Cann Group (ASX:CAN) - CEO, Peter Crock
CEO, Peter Crock
Source: Cannabis Club Australia
Market Herald logo

Subscribe

Be the first with the news that moves the market
  • Cann Group (CAN) has been awarded a $1.975 million grant under the Victorian Government’s Regional Jobs Fund
  • The grant money will be used for electricity upgrades at the planned cannabis cultivation facility near Mildura in regional Victoria
  • The development of Cann’s cannabis cultivation and processing facility is expected to generate around 150 new permanent jobs
  • Company shares are up 5.52 per cent, trading at 95.5 cents each

Cann Group (CAN) has been awarded a grant for up to $1.975 million under the Victorian Government’s Regional Jobs Fund.

The grant has been confirmed by Minister for Agriculture and Regional Development, Jaclyn Symes.

Cann Group will use the grant money to fund electricity upgrades at its planned state-of-the-art cannabis cultivation facility near Mildura in regional Victoria.

The Mildura Facility development has the potential to generate 150 new permanent jobs.

Cann chose Mildura as a suitable site for the cannabis cultivation and processing facility due to the region’s agricultural and horticulture heritage. Additionally, the local climate — specifically the days of sunshine and light intensity — attracted the company.

“This grant is a tangible demonstration of support from the Victorian Government in terms of our objectives,” CEO Peter Crock said.

“Our plans to develop commercial-scale production capacity at Mildura are central to the company’s strategy of being a fully integrated medicinal cannabis company that can service both Australian domestic patients and access valuable overseas markets,” Peter added.

Company shares are up 5.52 per cent and trading at 95.5 cents each at 1:15 pm AEST.

CAN by the numbers
More From The Market Herald

" Optiscan Imaging (ASX:OIL) signs distribution partnership for China

Optiscan Imaging (OIL) joins forces with a strategic distribution partner in China for its ViewnVivo device.
The Market Herald Video

" Imugene (ASX:IMU) confirms “favourable” survival outcome in HER-Vaxx phase two trial

Imugene (ASX:IMU) has reported positive final overall data from its phase two study of HER-Vaxx in…
The Market Herald Video

" Dimerix (ASX:DXB) closes recruitment for REMAP-CAP study

Dimerix (ASX:DXB) has formally closed recruitment of moderate state COVID-19 patients for REMAP-CAP's renin angiotensin system…
The Market Herald Video

" Starpharma (ASX:SPL) expands research program with Genentech

Starpharma (ASX:SPL) expands its research agreement with Genentech for its drug delivery technology, DEP.